Literature DB >> 27197234

Heterogeneity in Tumors and Resistance to EGFR TKI Therapy-Letter.

Kenichi Suda1, Christopher J Rivard2, Tetsuya Mitsudomi3, Fred R Hirsch2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27197234      PMCID： PMC5353479          DOI： 10.1158/0008-5472.CAN-15-2916

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  5 in total

Review 1.  Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny.

Authors:  Kenichi Suda; Hiroshi Mizuuchi; Yoshihiko Maehara; Tetsuya Mitsudomi
Journal:  Cancer Metastasis Rev       Date:  2012-12       Impact factor: 9.264

2.  Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.

Authors:  Kenichi Suda; Isao Murakami; Tatsuya Katayama; Kenji Tomizawa; Hirotaka Osada; Yoshitaka Sekido; Yoshihiko Maehara; Yasushi Yatabe; Tetsuya Mitsudomi
Journal:  Clin Cancer Res       Date:  2010-11-09       Impact factor: 12.531

3.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Authors:  Alexa B Turke; Kreshnik Zejnullahu; Yi-Long Wu; Youngchul Song; Dora Dias-Santagata; Eugene Lifshits; Luca Toschi; Andrew Rogers; Tony Mok; Lecia Sequist; Neal I Lindeman; Carly Murphy; Sara Akhavanfard; Beow Y Yeap; Yun Xiao; Marzia Capelletti; A John Iafrate; Charles Lee; James G Christensen; Jeffrey A Engelman; Pasi A Jänne
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

4.  Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.

Authors:  Margaret Soucheray; Marzia Capelletti; Inés Pulido; Yanan Kuang; Cloud P Paweletz; Jeffrey H Becker; Eiki Kikuchi; Chunxiao Xu; Tarun B Patel; Fatima Al-Shahrour; Julián Carretero; Kwok-Kin Wong; Pasi A Jänne; Geoffrey I Shapiro; Takeshi Shimamura
Journal:  Cancer Res       Date:  2015-08-17       Impact factor: 12.701

5.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Authors:  Pasi A Jänne; James Chih-Hsin Yang; Dong-Wan Kim; David Planchard; Yuichiro Ohe; Suresh S Ramalingam; Myung-Ju Ahn; Sang-We Kim; Wu-Chou Su; Leora Horn; Daniel Haggstrom; Enriqueta Felip; Joo-Hang Kim; Paul Frewer; Mireille Cantarini; Kathryn H Brown; Paul A Dickinson; Serban Ghiorghiu; Malcolm Ranson
Journal:  N Engl J Med       Date:  2015-04-30       Impact factor: 91.245
  5 in total
  4 in total

1.  Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer.

Authors:  Pei-Chih Lee; Yueh-Fu Fang; Hirohito Yamaguchi; Wei-Jan Wang; Tse-Ching Chen; Xuan Hong; Baozhen Ke; Weiya Xia; Yongkun Wei; Zhengyu Zha; Yan Wang; Han-Pin Kuo; Chih-Wei Wang; Chih-Yen Tu; Chia-Hung Chen; Wei-Chien Huang; Shu-Fen Chiang; Lei Nie; Junwei Hou; Chun-Te Chen; Longfei Huo; Wen-Hao Yang; Rong Deng; Katsuya Nakai; Yi-Hsin Hsu; Shih-Shin Chang; Tai-Jan Chiu; Jun Tang; Ran Zhang; Li Wang; Bingliang Fang; Ting Chen; Kwok-Kin Wong; Jennifer L Hsu; Mien-Chie Hung
Journal:  Cancer Cell       Date:  2018-12-10       Impact factor: 31.743

Review 2.  Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.

Authors:  Kenichi Suda; Paul A Bunn; Christopher J Rivard; Tetsuya Mitsudomi; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2016-09-15       Impact factor: 15.609

3.  Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.

Authors:  Kenichi Suda; Leslie Rozeboom; Christopher J Rivard; Hui Yu; Kim Ellison; Mary Ann C Melnick; Trista K Hinz; Daniel Chan; Lynn E Heasley; Katerina Politi; Tetsuya Mitsudomi; Fred R Hirsch
Journal:  Lung Cancer       Date:  2017-04-19       Impact factor: 5.705

4.  A novel EGFR-TKI inhibitor (cAMP-H3BO3complex) combined with thermal therapy is a promising strategy to improve lung cancer treatment outcomes.

Authors:  Yongpeng Tong; Chunliu Huang; Junfang Zhang
Journal:  Oncotarget       Date:  2017-05-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.